Institute News

EGEN announces phase I clinical trial for advanced ovarian cancer

HAIB News - Wed, 03/20/2013 - 12:59pm

News Outlet:  PR Newswire Date published:  March 20, 2013
HUNTSVILLE, Ala. -- EGEN, Inc. today announced that it has recently initiated a Phase I clinical trial of its novel immunotherapy agent, EGEN-001, in combination with PEGylated liposomal Doxorubicin or Lipodox for the treatment of recurrent ovarian cancer. The EGEN-sponsored trial is conducted by a network of researchers led by Gynecologic Oncology Group (GOG) at member institutions under an agreement between the GOG and EGEN, Inc. Premal Thaker, M.D., M.S., of Washington University School of Medicine, is the Study Chair for the trial.

read more

Categories: Institute News

GREAT workshop embraced by area educators

HAIB News - Wed, 03/06/2013 - 5:39pm

Nearly 130 educators from northern and central areas of Alabamaattended the February Genetic Resources Empowering Alabama Teachers workshop offered by HudsonAlpha. “Those who participated in the workshop received classroom kits with hands-on exercises in chromosomal arrangements, protein folding and the relationships between DNA, RNA and functional proteins,” said Madelene Loftin, HudsonAlpha biotechnology education specialist.
 

read more

Categories: Institute News